Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 80Years
All Genders
Healthy Volunteers
NCT07221344

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Led by Arrowhead Pharmaceuticals · Updated on 2026-04-15

112

Participants Needed

1

Research Sites

80 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

CONDITIONS

Official Title

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Who Can Participate

Age: 18Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Body mass index between 18.0 and 35.0 kg/m^2 at Screening
  • Not pregnant or breast-feeding
  • Able and willing to provide written informed consent before any study procedures
  • Participants of childbearing potential must use highly effective contraception and a condom during the study and for at least 90 days after the study or last dose
  • Participants must not donate sperm or eggs during the study and for at least 90 days after the study or last dose
  • Adults aged 50 to 80 years with clinical diagnosis of early Alzheimer's disease and biomarker confirmation
  • On stable doses of Alzheimer's disease medications for at least 8 weeks before screening and during screening until Day 1
  • Have a reliable caregiver or trial partner aged 18 or older, willing to accompany to visits and provide accurate information
Not Eligible

You will not qualify if you...

  • Blood pressure outside specified range in the protocol
  • HIV infection positive at screening
  • Positive for hepatitis B or C at screening
  • Intellectual disability or significant behavioral neuropsychiatric issues
  • Clinically significant heart, liver, or kidney disease
  • Any contraindications to lumbar puncture
  • Known or possible allergy to ARO-MAPT-SC or its ingredients
  • Additional criteria may apply per protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Research Site 1

Grafton, Auckland, New Zealand, 1010

Actively Recruiting

Loading map...

Research Team

M

Medical Monitor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here